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Abstract
Myelodysplastic syndromes (MDS) are often accompanied by autoimmune phenomena. The underlying
mechanisms for these associations remain uncertain, although T cell activation seems to be important. Human T-
lymphotropic virus (HTLV-1) has been detected in patients with myelodysplastic syndromes, mostly in regions of
the world which are endemic for the virus, and where association of HTLV-1 with rheumatological manifestation is
not rare. We present here the case of a 58 year old man who presented with cytopenias, leukocytoclastic vasculitis
of the skin and glomerulopathy, and was diagnosed as MDS (refractory anemia with excess blasts - RAEB 1). The
patient also tested positive for HTLV-1 by PCR. After 8 monthly cycles of 5-azacytidine he achieved a complete
hematologic remission. Following treatment, a second PCR for HTLV-1 was carried out and found to be negative.
This is the first report in the literature of a HTLV-1-positive MDS with severe autoimmune manifestations, which
was treated with the hypomethylating factor 5-azacitidine, achieving cytogenetic remission with concomitant
resolution of the autoimmune manifestations, as well as HTLV-1-PCR negativity. HTLV-1-PCR negativity may be due
to either immune mediated clearance of the virus, or a potential antiretroviral effect of 5-azacytidine. 5-azacytidine
is known for its antiretroviral effects, although there is no proof of its activity against HTLV-1 infection in vivo.
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Background
The association of myelodysplasia with autoimmune
phenomena is well established for more than 20 years,
as evidenced by several case reports and small patient
series. HTLV-1, the first described human retrovirus,
and cause of adult T cell leukemia/lymphoma (ATLL)
has been associated to myelodysplastic syndromes. In
areas endemic for the virus, serologic positivity for
HTLV-1 is not very rare in patients with myelodysplas-
tic syndromes [1]. Moreover there are several reports of
autoimmune manifestations in HTLV-1 positive patients
[2,3]. These correlations are very unusual in non-ende-
mic areas, such as Greece.
Case presentation
A 58 year old man was admitted to our clinic due to a 6-
month history of night sweats, anorexia, and weight loss. 6
months ago he had an influenza-like illness and 4 months
before admission, he developed ptosis of his left eyelid,
with no other neurologic signs and symptoms and a nega-
tive brain MRI and carotid artery triplex ultrasound. The
symptom resolved without any neurologic sequelae. One
month before admission, he developed erythema nodosum
on his left leg. His past medical history was unremarkable.
The physical examination did not reveal any abnorm-
alities. He had no liver, spleen, or lymph node enlarge-
ment. No rash on the skin or mucosa was noted.
His complete blood count showed anemia, leucopenia
and thrombocytopenia. He also had increased serum
markers of inflammation, a marked hypergammaglobuli-
nemia and a slightly affected renal and liver function
along with a normal urinalysis Table 1. The evaluation
included antibody testing for viral infections (HBV,
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syphilis, Ricketsiae, and Toxoplasma. His immunologic
profile showed low titers of antinuclear antibodies
(1:80), high titers of Reumatoid Factor (250 IU/mL), and
positive anti-citrullinated protein antibodies (17.7 U/mL,
reference value < 15 U/mL), with complement levels
(C3/C4/C50), antistreptolysin O titer, antimitochondrial
andibodies, anti-smooth muscle antibodies, anti nutro-
philic cytoplasmic antibodies, anti-b2-glycoprotein-I
antibody, and anticardiolipin antibodies all being nor-
mal. Cryoglobulins were also negative, as was the direct
Coombs test. The chest X-ray was normal, as was the
heart ultrasound. A PPD (purified protein derivative)
skin test was performed and found negative.
He underwent an extensive imaging evaluation with a
chest, abdominal and pelvic CT scan and a brain MRI,
as well as a percutaneous liver biopsy that revealed a
mild steatohepatitis.
Finally, he had a bone marrow aspiration and biopsy
that confirmed the diagnosis of myelodysplastic syn-
drome with 8% blasts (RAEB-1, WHO 2008) [4] (Figures
1 and 2), while immunophenotypic analysis revealed the
myeloid origin of the blasts. Karyotypic analysis of the
bone marrow showed a pseudo-hypodiploid abnormal
clone of 45, X-Y in 24 out of 25 studied metaphases.
The patient also tested positive for HTLV-1 with a diag-
nostic PCR, both in blood and bone marrow. The result
was confirmed in a second sample. A T-cell receptor
gene clonality assay was carried out and a clonal popula-
tion of T cells was revealed.
During his hospitalization he presented fever, a vascu-
litic rash at his neck, torso and arms (histopathologic
examination showed a leukocytoclastic vasculitis), along
with deterioration of his anemia (Ht = 26%), thrombocy-
topenia (20 × 10
9/L), liver (ALP 1216 U/L, SGOT 61 U/
L, SGPT 124 U/L) and renal function (Creatinine 1.6
mg/dL), and an abnormal urine sediment (1400 mg
urine protein per day, 40-50 red blood cells per high
power field [70% of them being of glomerular origin]
and granular casts). A renal biopsy was scheduled in
order to evaluate his nephritic syndrome, but was can-
celled due to severe thrombocytopenia with positive
antiplatelet antibodies.
After an unsuccessful course of antibiotics, in an effort
to control fever, rash and glomerulopathy, methylpred-
nisolone was administered (40 mg bis) resulting in rapid
improvement of his clinical findings and biochemical
profile. Methotrexate 10 mg/week PO was added to the
regimen after 2 unsuccessful attempts of steroid taper-
ing, while, due to persistent and severe pancytopenia, he
was treated with a course 8 monthly cycles of 5-azacyti-
d i n ei nad o s eo f7 5m g / m
2/d for 7 days. He achieved
complete hematologic remission that was further con-
firmed via immunophenotypic analysis.
Fifteen months after initial diagnosis, bone marrow
karyotypic and molecular testing (MLPA and QF-PCR
for several chromosomal regions, including 2p, 5q,
6q25-26, 7p12.2, 8q24.21, 9p13.2, 9p21.3, 10q23,
11q22.3, 12p13.2, 13q14, 17p13.1, and 21q22.1, and for
JAK2 V617F mutation) revealed no abnormalities.
About 15 months after the first positive PCR for HTLV-
1, and 11 months after initiation of azacytidine, a second
test was carried out and was found negative.
One month later, the patient underwent allogeneic
peripheral blood stem cell transplantation from a fully
matched unrelated donor with a once daily intravenous
Table 1 Complete blood count with differential, and biochemical profile of the patient upon his first admission
Ht: 31.2% Hb: 10.4 g/dL MCV: 94.2 fl RET: 0.84% PLT: 130 × 10
9/L.
WBC: 2.6 × 10
9/L Differential: neutrophils 37%, lymphocytes: 53%, monocytes: 4%, eosinophils: 1%, basophils: 5%, with several neutrophils
showing granulation disorders and small cytoplasmic vacuoles
BUN: 33 mg/dL Cr: 1.4 mg/dL ALP: 399 U/L gGT: 127 U/L AST: 27 U/L ALT: 66 U/L
ESR: 135 mm/1st hour CRP: 60 mg/L
Figure 1 Patient’sb o n em a r r o ws m e a r ss h o w i n gd y s p l a s t i c
changes of erythroid cells and immature/dysplastic forms of
myeloid cells.
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regimen. A bone marrow aspirate on day +30 demon-
strated trilineage engraftment and complete chimera
(100% donor). On day +58 the patient developed grade
II graft versus host disease (GVHD) of the skin that
responded promptly to treatment with steroids. Cur-
rently, 8 months after transplantation, the patient
remains in complete remission.
Discussion
The association of myelodysplasia with autoimmunity is
well established for almost 20 years and has been con-
firmed by clinical and laboratory data [5,6].
T h e r ea r es e v e r a lr e p o r t si nt h el i t e r a t u r ec o r r e l a t i n g
various autoimmune manifestations such as leukocyto-
clastic vasculitis [7], relapsing polychondritis [8], polyar-
teritis nodosa, Grave’sd i s e a s e ,S j ö g r e n ’ss y n d r o m e[ 9 ] ,
Wegener’s granulomatosis [10], bronchiolitis obliterans
[11], autoimmune hemolytic anemia [12], and thrombo-
cytopenia [13,14], red cell aplasia [15], dermatomyositis
[16], peripheral polyneuropathy and inflammatory bowel
disease [17], giant cell arteritis/polymyalgia rheumatica
[18,19], and Addison’s disease [20].
MDSs have been linked to several types of glomerular
diseases, such as glomerulosclerosis, membranous
nephropathy, IgA nephropathy, and ANCA associated
nephropathy [21-25]. Unfortunately, in our case, due to
lack of histopathologic examination, only speculations
c a nb em a d ea b o u tt h et y p eo ft h ep a t i e n t ’s renal
disease.
Both the innate and adoptive immune system have
been implicated in the autoimmune manifestations of
patients with MDS in several studies evaluating T cell
activation, function, and kinetics, as well as associations
with the HLA system [26,27].
A large number of reports favor the use of immunore-
gulatory treatments [28] such as antithymocyte globu-
line, cyclosporine, thalidomide, steroids, mycophenolate
mofetil, anti-TNF, and methotrexate in patients with
MDS and autoimmune manifestations. More recently,
guidelines for the use of immunomodulatory treatment
for MDS have been proposed [29].
In our case, myelodysplastic syndrome and autoim-
mune phenomena were also accompanied by a positive
PCR for HTLV-1. HTLV-1 has been implicated in the
pathogenesis of ATLL and tropical spastic paraparesis.
Although the virus is oncogenic, it neither induces
oncogenesis by encoding oncogenes, nor does it inte-
grate into the host genome to disrupt host gene expres-
sion. Rather, viral gene products interact with host
proteins (mainly transcription factors) altering their
function.
It is estimated that 10-20 million people are infected
by the virus worldwide. In endemic areas (southern
Japan, the Caribbean, South America, the Melanesian
islands, Papua New Guinea, the Middle East and central
and southern Africa) seroprevalence ranges from 3% to
30%. In non-endemic areas, such as Greece, seropreva-
lence is less than 1%. Seropositivity among blood donors
in Greece was reported to be 0.009% in a large multi-
center study [30].
Transmission of the virus is mainly achieved through
breast feeding, sexual intercourse, inappropriate sterili-
zation procedures and blood transfusion or injection
drug use. Our patient claimed not to be an injection
drug user, and had never been transfused in the past.
His wife tested negative for HTLV-1.
In the literature serologic positivity for the virus has
been detected in patients with myelodysplastic syn-
dromes in both endemic [31] and non endemic regions
for the virus [32].
Most studies about the prevalence of HTLV-1 in
h e m a t o l o g i cd i s e a s e sc o m ef r o mJ a p a nw h e r et h ei n f e c -
tion is endemic. Several case reports suggest the possible
association between immune thrombocytopenia (ITP)
and HTLV-1 infection [33]. Recently Inoue et al. studied
HTLV-1 prevalence in patients with RAEB/RAEBt and
AML [31]. The high prevalence (28.3%) of HTLV-1
infection in the studied group of patients with RAEB/
RAEBt is very interesting but cannot be extrapolated to
patients of non-endemic regions. There is only one
study in the literature coming from a non endemic
region that suggests a possible role of HTLV-1 infection
in the pathogenesis of hematologic diseases other than
ATLL, especially MDS [32].
Association of the virus with rheumatologic manifesta-
tions is not rare and includes uveitis, chronic
Figure 2 Typical dysplastic megacaryocytes.
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cytic alveolitis, polymyositis, and fibromyalgia, but all
these reports come from regions endemic for the
HTLV-1 infection [33-40]. Moreover, there are 3
reports, coming from endemic regions, associating
HTLV-1 with glomerulonephritis and interstitial nephri-
tis [35,41,42].
Treatment of the diseases caused by HTLV-1 is pro-
blematic. There have been only limited studies of speci-
fic antiretroviral therapy using nucleoside analogue
reverse transcriptase inhibitors for HTLV-1 infection
[43-45].
Azacytidine and its deoxy derivative, decitabine (5-aza-
2’deoxycytidine), are FDA-approved agents for the treat-
ment of low and high risk patients with MDS. Azacyti-
dine is incorporated into DNA and RNA by
methyltransferases and acts as a false substrate and a
potent inhibitor of methyltransferases. This results in
reduction of DNA methylation (hypomethylating or
demethylating agent) affecting the binding of cell regula-
tion proteins to the DNA/RNA substrate [46,47]. DNA
hypermethylation at the CpG islands has been described
in MDS. These CpG islands are targets for transforma-
tion-associated aberrant hypermethylation activity dur-
ing leukemogenesis. Moreover, aberrant CpG island
hypermethylation seems to be an important multistep
process in the development of ATLL [48].
It has been shown that 5-azacytidine inhibits human
immunodeficiency virus type 1 (HIV-1) replication [49].
This antiviral activity can be attributed to an increase in
the frequency of viral mutants, achieved by incorpora-
tion of its derivative 5-aza-2’-deoxycytidine into the viral
DNA. The same may apply to other retroviruses such as
HTLV-1, for which it has been shown that its transcrip-
tional activity is regulated by methylation [50]. Recently,
a closely related molecule, decitabine, has been success-
fully used in a trial to reduce HIV infectivity [51]. The
antiviral activity of the drug has been attributed to an
increase in the mutational load that inhibits the genera-
tion of infectious progeny virus from provirus.
The antiretroviral activities of hypomethylating factors,
such as decitabine and 5-azacytidin are the subject of
several current studies. One of them suggests a more
specific role of 5-azacytidine in the treatment of ATLL,
as it shows a growth inhibition of leukemic cells, offer-
ing a potential new therapeutic approach to improve the
poor outcomes associated with ATLL [52].
Although in our case, HTLV-1 negativity may have
resulted from other unidentified factors, such as
immune restoration following treatment, our case may
be another example of drug repositioning, were azaciti-
dine administered to treat MDS, had also an effect on
HTLV-1 replication, resulting into a negative PCR for
the virus several months following treatment.
Conclusions
T h i si sau n i q u ec a s eo fap a t i e n tw i t hR A E B - 1 ,a c c o m -
panied by severe autoimmune manifestations, that was
infected with HTLV-1 in a region non-endemic for the
virus. The patient achieved a complete remission of his
hematologic disease and autoimmune manifestations
after treatment with 5-azacytidine, while several months
later he tested negative for HTLV-1 by nested PCR, a
fact that can be linked to the, already identified by other
studies, antiretroviral action of the drug.
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